Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

ENCORE1 Study Group

Research output: Contribution to journalArticlepeer-review

127 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial'. Together they form a unique fingerprint.

Medicine & Life Sciences